

Narciso Olvera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12050337/publications.pdf>

Version: 2024-02-01

32
papers

2,876
citations

236925

25
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

5434
citing authors

#	ARTICLE	IF	CITATIONS
1	Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1690-1704.	3.8	323
2	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. <i>Nature Genetics</i> , 2014, 46, 424-426.	21.4	291
3	Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1503-1513.	6.3	231
4	Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. <i>Modern Pathology</i> , 2012, 25, 625-636.	5.5	202
5	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. <i>JAMA Oncology</i> , 2016, 2, 1434.	7.1	189
6	Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. <i>Nature Communications</i> , 2017, 8, 990.	12.8	169
7	Clinicopathologic Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1745-1753.	1.6	152
8	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. <i>Journal of the National Cancer Institute</i> , 2018, 110, 787-790.	6.3	123
9	Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant. <i>Science Advances</i> , 2018, 4, eaaq1090.	10.3	121
10	Genomic Complexity and AKT Dependence in Serous Ovarian Cancer. <i>Cancer Discovery</i> , 2012, 2, 56-67.	9.4	109
11	Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma. <i>PLoS ONE</i> , 2010, 5, e10358.	2.5	90
12	Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type. <i>American Journal of Surgical Pathology</i> , 2016, 40, 395-403.	3.7	87
13	Heterogenic Loss of the Wild-Type BRCA Allele in Human Breast Tumorigenesis. <i>Annals of Surgical Oncology</i> , 2007, 14, 2510-2518.	1.5	82
14	Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 147-159.	3.7	77
15	Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2004, 93, 301-306.	1.4	76
16	Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. <i>Modern Pathology</i> , 2016, 29, 60-66.	5.5	62
17	BRCA1 Immunohistochemistry in a Molecularly Characterized Cohort of Ovarian High-Grade Serous Carcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 138-146.	3.7	54
18	Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers. <i>Cancer Research</i> , 2004, 64, 5051-5053.	0.9	51

#	ARTICLE	IF	CITATIONS
19	Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. <i>Cancer Discovery</i> , 2021, 11, 362-383.	9.4	50
20	Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 371-374.	1.2	50
21	Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses. <i>Gynecologic Oncology</i> , 2018, 150, 127-135.	1.4	41
22	Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions. <i>Breast Cancer Research</i> , 2012, 14, R103.	5.0	38
23	Molecular Subtypes of Uterine Leiomyosarcoma and Correlation with Clinical Outcome. <i>Neoplasia</i> , 2015, 17, 183-189.	5.3	33
24	Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. <i>Molecular Oncology</i> , 2015, 9, 772-782.	4.6	32
25	Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. <i>ACS Chemical Biology</i> , 2017, 12, 2085-2096.	3.4	32
26	Tissue preparation for laser capture microdissection and RNA extraction from fresh frozen breast tissue. <i>BioTechniques</i> , 2007, 43, 41-48.	1.8	26
27	Clinicopathologic Analysis of Matched Primary and Recurrent Endometrial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1771-1781.	3.7	22
28	miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. <i>Scientific Reports</i> , 2017, 7, 3614.	3.3	22
29	Blocking and Randomization to Improve Molecular Biomarker Discovery. <i>Clinical Cancer Research</i> , 2014, 20, 3371-3378.	7.0	18
30	Genetic predisposition to bevacizumab-induced hypertension. <i>Gynecologic Oncology</i> , 2017, 147, 621-625.	1.4	17
31	A pair of datasets for microRNA expression profiling to examine the use of careful study design for assigning arrays to samples. <i>Scientific Data</i> , 2018, 5, 180084.	5.3	5
32	Frequency of <i>BRCA1</i> and <i>BRCA2</i> germline mutations in uterine serous carcinomas and uterine carcinosarcomas. <i>Journal of Clinical Oncology</i> , 2018, 36, e13521-e13521.	1.6	1